TAS::75 0843::TAS HORMONE THERAPY AND COGNITIVE AGING IN OLDER AND YOUNGER POSTM

TAS::75 0843::TAS 激素治疗与老年人和年轻人 POTM 中的认知老化

• 批准号: 8333760
• 负责人: Sally Ann SHUMAKER
• 金额: $ 139.01万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-06 至 2016-05-05
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8333760
• 关键词: Acetates; Age-Years; Cardiovascular system; Cognition; Cognitive; Cognitive aging; Combined Modality Therapy; Conjugated Equine Estrogens; Conjugated Estrogens; Contracts; Coronary heart disease; Dementia; Early treatment; Health; Hormones; Impaired cognition; Long-Term Effects; Memory; Menopause; Outcome; Pharmaceutical Preparations; Pharmacologic Substance; Placebos; Postmenopause; Prempro; Progesterone; Randomized; Randomized Clinical Trials; Risk; Screening procedure; Tablets; Testing; Time; Uterus; Woman; Women' s Health; cognitive function; cohort; design; epidemiology study; follow-up; hormone therapy; prospective

The Women¿s Health Initiative (WHI) randomized clinical trials of hormone therapy (HT) were designed to determine whether HT had beneficial effects on health outcomes, especially cardiovascular health, in postmenopausal women. Women without uteri were randomly assigned to take one daily tablet containing either conjugated equine estrogens (CEE), 0.625 mg (Premarin, Wyeth Pharmaceuticals), or a matching placebo, and women with uteri were randomly assigned to take one daily tablet containing either CEE, 0.625 mg, and medroxy progesterone acetate (MPA), 2.5 mg, (Prempro, Wyeth Pharmaceuticals) or a matching placebo. The WHI Memory Study (WHIMS) was an ancillary to the WHI and investigated the effects of HT on risk of probable dementia and any cognitive impairment and on changes in global cognition over time. The WHI and ancillary WHIMS study were stopped earlier than planned for both the combination therapy (in 2002) and CEE-Alone (in 2004) because these treatments increased health risks and did not protect against coronary heart disease. Although study medications were discontinued, follow-up assessments continued. The purpose of the present contract is to continue prospective follow-ups, including dementia screening and cognitive assessments, of women in the WHIMS Epidemiology of Cognitive Health Outcomes (WHIMS-ECHO) cohort In addition, this contract continues prospective cognitive assessments in the more recently initiated Women¿s Health Initiative Memory Study of Younger Women (WHIMS-Y) to determine the long-term impact of random assignment to postmenopausal HT among women who were 50-54 years of age at the time they were randomized in the WHI hormone trials. WHIMS-Y tests the ¿window of opportunity¿ hypothesis that HT shortly after menopause will confer benefit to later cognitive health.

女人们的健康倡议（WHI）的随机临床试验的激素治疗（HT）的目的是确定是否HT对健康的结果，特别是心血管健康的有益影响，在绝经后妇女。无子宫的妇女被随机分配每天服用一片含有0.625 mg结合马雌激素（CEE）（倍美力，惠氏制药）或匹配安慰剂的片剂，有子宫的妇女被随机分配每天服用一片含有0.625 mg CEE和2.5 mg醋酸甲羟孕酮（MPA）（Prempro，惠氏制药）或匹配安慰剂的片剂。WHI记忆研究（WHIMS）是WHI的辅助研究，研究HT对可能的痴呆和任何认知障碍的风险以及随着时间的推移对整体认知变化的影响。联合治疗（2002年）和CEE单药治疗（2004年）的WHI和辅助WHIMS研究均早于计划停止，因为这些治疗增加了健康风险，并且不能预防冠心病。虽然停用了研究药物，但继续进行随访评估。本合同的目的是继续对WHIMS认知健康结局流行病学中的妇女进行前瞻性随访，包括痴呆症筛查和认知评估（WHIMS-ECHO）队列此外，该合同继续在最近启动的女性中进行前瞻性认知评估。的年轻女性健康主动记忆研究（WHIMS-Y），以确定随机分配到50岁以下的绝经后HT妇女的长期影响。在WHI激素试验中随机分配时年龄为54岁。WHIMS-Y测试了“机会之窗”假设，即绝经后不久的HT将有益于以后的认知健康。